Q32 Bio Inc.

Healthcare · Biotechnology · United States

Last price 8.87 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 264.06M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatm...